NEW YORK – A new case study is raising questions as to whether larotrectinib (Bayer's Vitrakvi) might be considered earlier on in the course of treatment for NTRK-fusion positive solid tumors, specifically for young patients with high-grade gliomas.
In 2018, when larotrectinib first received accelerated approval from the US Food and Drug Administration, it became the second oncology agent approved with a tumor-agnostic indication.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
